is looking for the next breakout opportunity!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Still watching for re-entry
Appreciate it!
List of reasons would be helpful :)
Sold this morning and waiting to see how the market reacts to financial results.
Love the chart, but felt better watching the stock on the other side of the fence for now.
Yes, very glad to see it, but hoping the chart adds strength from here.
Looking forward to tomorrow's action. Feel a little sorry for those who were shaken out this morning, but they can hit that ask for us anytime they want :).
MELA Sciences to Present at Upcoming Investor Conferences
IRVINGTON, N.Y., Jan. 28, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (MELA), the medical device company focused on the design, development and commercialization of MelaFind(R), today announced that Joseph V. Gulfo, MD, President and CEO, will be participating at three upcoming investor conferences.
• On Thursday, February 14, 2013, Dr. Gulfo will give a presentation at the Leerink Swann Global Healthcare Conference in New York. To access a live webcast of this presentation, visit the investor relations section of www.melasciences.com. A replay will be available on the company's website for two weeks following the presentation.
• On Wednesday, February 27, 2013, Dr. Gulfo will participate in the Lazard Capital Markets 5th Annual Medical Technology, Healthcare IT and Life Science Tools Snowbird Conference in Utah.
• On Wednesday, March 6 2013, Dr. Gulfo will give a presentation at the Cowen & Company 33rd Annual Healthcare Conference in Boston. To access a live webcast of this presentation, visit the investor relations section of www.melasciences.com. A replay will be available on the company's website for two weeks following the presentation.
About MELA Sciences, Inc.
MELA Sciences is a medical device company focused on the commercialization of its flagship product, MelaFind(R), and its further design and development. MelaFind is a non-invasive tool to provide additional information to dermatologists during melanoma skin examinations. The device uses light from visible to near-infrared wavelengths to evaluate skin lesions up to 2.5 mm beneath the skin. The device provides information on a lesion's level of morphologic disorganization to provide additional objective information that may be used by dermatologists in the biopsy decision-making process. MelaFind has been approved by the US Food and Drug Administration for use in the US. In addition, MelaFind has received CE Mark approval and is approved for use in the European Union.
For more information on MELA Sciences, visit www.melasciences.com.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as "expects," "contemplates," "anticipates," "plans," "intends," "believes," "assumes," "predicts" and variations of such words or similar expressions that predict or indicate future events or trends, or that do not relate to historical matters. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved. Actual results may differ materially from our beliefs or expectations due to financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the company and the medical device industry in general, as well as more specific risks and uncertainties facing the company such as those set forth in its reports on Forms 10-Q and 10-K filed with the U.S. Securities and Exchange Commission (the "SEC"). Factors that might cause such a difference include whether MelaFind(R) achieves market acceptance or becomes commercially viable. Given the uncertainties affecting companies in the medical device industry such as the Company, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. The Company urges you to carefully review and consider the disclosures found in its filings with the SEC which are available at www.sec.gov and www.melasciences.com.
I'm in... watching close though.
Same to you! TY!
Got out with plans to get back in.
Have passed up too many other swing trades in this stock the past two years.
CYTK having an awesome climb here.
Still holding on from way back.
Looks like CYTK remembered my birthday today.
Still a ways from break-even for me though.
I believe odds are in your favor here.
Evidently these aren't as important as they once were.
Haven't really kept up with them, but thought I'd check in today and see what people buy these days.
Wow, no posts here?
Used to love watching these back when some went up over 200%
Same here
Nope, just slow start.
Still holding that CYTK - hope my patience is rewarded! Still a believer.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=78499264
CYTK-4 Buy ratings past month
Cytokinetics Stock Rating Reaffirmed by Canaccord Genuity (CYTK)
http://www.jagsreport.com/2012/08/cytokinetics-stock-rating-reaffirmed-by-canaccord-genuity-cytk/
Canaccord Genuity reiterated their buy rating on shares of Cytokinetics (NASDAQ: CYTK) in a research note issued to investors on Wednesday.
CYTK has been the subject of a number of other recent research reports. Analysts at Cowen initiated coverage on shares of Cytokinetics in a research note to investors on Wednesday. They set an outperform rating on the stock.
Separately, analysts at Rodman & Renshaw reiterated an outperform rating on shares of Cytokinetics in a research note to investors on Tuesday. They now have a $2.00 price target on the stock.
Finally, analysts at Needham & Company initiated coverage on shares of Cytokinetics in a research note to investors on Monday, July 2nd. They set a buy rating and a $2.50 price target on the stock.
That's encouraging...
Sure wish I was playing the swings on this one instead of holding what I bought last year.
Looks like we'll get a good pop today. Last premarket trade was at $1.14.
Holding mine still from higher.
I think we have something special here - just never know with these pharmaceuticals.
Thanks for the heads up
Looks good
Will have to keep it on watch
Looks like SIHI may break out
Held a cent over the 50sma today
Excellent chart and annotations
Definitely setup nicely
Cytokinetics Announces Initiation of Second Cohort of Ongoing Phase II Clinical Trial Evaluating CK-2017357 in Patients With ALS
SOUTH SAN FRANCISCO, CA -- (MARKET WIRE) -- 11/01/11 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the initiation of a second cohort, or Part B, of an ongoing Phase II clinical trial of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS). CK-2017357, a fast skeletal muscle troponin activator, selectively activates the fast skeletal muscle troponin complex by increasing its sensitivity to calcium, which increases skeletal muscle force in response to neuronal input and delays the onset and reduces the degree of muscle fatigue. CK-2017357 is the lead drug candidate that has emerged from the company's skeletal muscle contractility program.
Part B of this clinical trial, a double-blind, randomized, placebo-controlled evaluation of the safety and tolerability of multiple doses of CK-2017357 in patients with ALS, is designed to enroll patients who are also receiving riluzole. In Part B, an estimated 24 patients are planned to be enrolled at eight to ten study centers in the United States . Patients in the trial will be randomized to one of four different treatment groups, to receive daily oral doses of placebo, 125 mg, 250 mg, or 375 mg of CK-2017357, respectively, in addition to 50 mg of riluzole for two weeks; clinical assessments will take place at pre-determined times during the course of treatment. Patients will also participate in follow-up evaluations one week after their final dose.
The primary objective of this clinical trial is to assess the safety and tolerability of CK-2017357, after multiple oral doses to steady state plasma concentrations, in patients with ALS who are also receiving riluzole. A secondary objective of this clinical trial is to evaluate the ALS Functional Rating Scale-revised (ALSFRS-R), other measures of pulmonary function, muscle strength and fatigue, and physician and patient global assessments in these patients while receiving two weeks of treatment with CK-2017357 at the indicated doses or placebo. Additional information about this trial can be found at www.clinicaltrials.gov.
Cytokinetics recently concluded enrollment of the first cohort, or Part A, of this trial which was designed to evaluate the safety and tolerability, pharmacokinetic and pharmacodynamics of multiple fixed daily doses of CK-2017357 in ALS patients who are not receiving riluzole. The company anticipates that data from Part A of this trial will be presented at the 22nd International Symposium on ALS and Motor Neurone Diseases Meeting in Sydney, Australia to be held November 30-December 2, 2011 .
Development Status of CK-2017357 in ALS
Cytokinetics is developing CK-2017357, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. CK-2017357 is currently the subject of a Phase II clinical trials program and has been granted orphan-drug designation by the U.S. Food and Drug Administration for the potential treatment of ALS, a debilitating disease of neuromuscular impairment in which CK-2017357 demonstrated potentially clinically relevant pharmacodynamic effects in a Phase IIa Evidence of Effect clinical trial. In that trial, the single doses of CK-2017357 evaluated appeared safe and generally well-tolerated. In addition, both patients and investigators perceived a positive change in the patients' overall status, in a dose-dependent fashion, at 6 hours after dosing with CK-2017357, based on a Global Assessment in which the patient and the investigator each independently assessed patients' status compared to prior to dosing. Furthermore, there was a clear relationship between improvements in Global Assessments and the CK-2017357 plasma concentration. Also at this 6-hour time point, there was a trend towards decreased muscle fatigability, as evidenced by data from a test of sub-maximal hand-grip endurance. Data from this clinical trial also demonstrated a statistically significant, dose-related increase in the maximum volume of air patients could inhale and exhale in ten seconds (Maximum Voluntary Ventilation) at both 6 and 24 hours after 500 mg of CK-2017357, as well as small but statistically significant increases in maximum strength of certain muscle groups tested.
Cytokinetics recently met with the U.S. Food and Drug Administration Center for Drug Evaluation and Research's Division of Neurology Products to discuss the progress in the development of CK-2017357 as a potential treatment for patients with ALS and the company's strategy for its further development, including potential registration strategies. Based on this discussion, Cytokinetics is assessing options that may enable the initiation of a clinical trial of CK-2017357 in ALS patients that could potentially serve as a pivotal trial for global registration purposes.
Background on Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that afflicts 20,000 to 30,000 people in the United States . Approximately 5,600 new cases of ALS are diagnosed each year. The average life expectancy of an ALS patient is approximately three to five years and only 10% of patients survive for more than 10 years. Death is usually due to respiratory failure because of diminished strength in the skeletal muscles responsible for breathing. Few treatment options exist for these patients, resulting in a high unmet need for new therapeutic options to address the symptoms and modify the disease progression of this grievous illness.
Background on Cytokinetics Skeletal Muscle Contractility Program
CK-2017357, a fast skeletal muscle troponin activator, is the lead drug candidate from the company's skeletal muscle contractility program. CK-2017357 selectively activates the fast skeletal muscle troponin complex by increasing its sensitivity to calcium, leading to an increase in skeletal muscle force. This mechanism of action has demonstrated encouraging pharmacological activity in preclinical models that may relate to the potential treatment of diseases associated with aging, muscle wasting or neuromuscular dysfunction. Skeletal muscle contractility is driven by the sarcomere, the fundamental unit of skeletal muscle contraction. The sarcomere is a highly ordered cytoskeletal structure composed of skeletal muscle myosin, the cytoskeletal motor that is directly responsible for converting chemical energy into mechanical force, as well as actin, and a set of regulatory proteins, troponins and tropomyosin, which make the actin-myosin interaction dependent on changes in intracellular calcium levels. Cytokinetics' skeletal muscle contractility program is focused to the discovery and development of small molecule skeletal sarcomere activators and leverages Cytokinetics' expertise developed in its ongoing discovery and development of cardiac sarcomere activators, including the cardiac myosin activator omecamtiv mecarbil, now in clinical development as a potential treatment for heart failure. Skeletal sarcomere activators have demonstrated pharmacological activity in preclinical models that may lead to new therapeutic options for diseases associated with aging, muscle wasting and neuromuscular dysfunction. The clinical effects of muscle wasting, fatigue and loss of mobility can range from decreased quality of life to, in some instances, life-threatening complications. By directly improving skeletal muscle function, a small molecule activator of the skeletal sarcomere may potentially enhance physical performance and quality of life in aging patients.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil (formerly CK-1827452), is in clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan ) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing CK-2017357, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. CK-2017357 is currently the subject of a Phase II clinical trials program and has been granted orphan-drug designation by the U.S. Food and Drug Administration for the potential treatment of amyotrophic lateral sclerosis, a debilitating disease of neuromuscular impairment in which CK-2017357 demonstrated potentially clinically relevant pharmacodynamic effects in a Phase IIa trial. Cytokinetics is also conducting research and non-clinical development of compounds that inhibit smooth muscle contractility and which may be useful as potential treatments for diseases and conditions associated with excessive smooth muscle contraction, such as bronchoconstriction associated with asthma and chronic obstructive pulmonary disorder (COPD). In addition, prior Cytokinetics' research generated three anti-cancer drug candidates that have progressed into clinical development: ispinesib, SB-743921 and GSK-923295. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities, including plans for and the initiation, conduct, scope, design and results of clinical trials for CK-2017357, the significance and utility of clinical trial results for CK-2017357 and the anticipated timing for the availability of clinical trial data; the potential size of markets for CK-2017357; the properties and potential benefits of CK-2017357 and Cytokinetics' other drug candidates and potential drug candidates, including CK-2017357's potential utility in the treatment of patients with ALS; and planned presentations by Cytokinetics . Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results, patient enrollment for or conduct of clinical trials may be difficult or delayed, Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy, the U.S. Food and Drug Administration (FDA) or foreign regulatory agencies may delay or limit Cytokinetics' or its partners' ability to conduct clinical trials, the FDA may not grant CK-2017357 orphan drug exclusivity in ALS even if it is approved for marketing, and Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; Amgen's decisions with respect to the design, initiation, conduct, timing and continuation of development activities for omecamtiv mecarbil; Cytokinetics may incur unanticipated research and development and other costs or be unable to obtain additional financing necessary to conduct development of its products on acceptable terms, if at all; funding from the National Institute of Neurological Disorders and Stroke may not be available in future periods; Cytokinetics may be unable to enter into future collaboration agreements for its drug candidates and programs on acceptable terms, if at all; standards of care may change, rendering Cytokinetics' drug candidates obsolete; competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target; and risks and uncertainties relating to the timing and receipt of payments from its partners, including milestones and royalties on future potential product sales under Cytokinetics' collaboration agreements with such partners. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission .
Contact: Christopher S. Keenan Director, Investor & Media Relations (650) 624-3000
Glad I sold near the resistance level... always trust the chart!
Never intended to stay out completely though... looking good here around $1... didn't expect it to fall this quick from $1.25 though.
Man, I gotta get this and show it to the guys at the gym LOL
I'd say it's a good bet. Would have a stop in place though.
Not sure how long your holding, but don't forget Windows 8 is expected next year and there could be a similar run-up as there was for Windows 7.
I doubt Windows 8 will do well though. Every other OS they put out isn't received well (Windows ME, Windows Vista for example). Just could squeeze as the launch date approaches.
Sad to see this trading for half a dollar
This is an odd one... but I still like it.
Had some "news" this morning
Friday, September 23 2011 9:25 AM, EST CAMAC Energy to Present at the UBS Global Oil & Gas Conference Business Wire "Press Releases - English"
HOUSTON --(BUSINESS WIRE)-- CAMAC Energy Inc . (NYSE Amex: CAK), a U.S.-based energy company engaged in the exploration, development and production of oil and gas, today announced that Edward Caminos , Senior Vice President and CFO, will present and meet with investors at the UBS Global Oil & Gas Conference on Tuesday, September 27, 2011 in London .
An electronic version of the presentation will be available on CAMAC Energys website at http://www.camacenergy.com under the Investors Events & Presentations section.
About CAMAC Energy Inc.
CAMAC Energy Inc . (NYSE Amex: CAK) is a U.S.-based energy company engaged in the exploration, development and production of oil and gas. The Company currently has operations in Nigeria and, through its Pacific Asia Petroleum subsidiaries, in China . The Company's principal assets include interests in OML 120 and OML 121, offshore oil leases in deepwater Nigeria that started production from the Oyo Oilfield in December 2009 , and a 100% interest in the Zijinshan Block gas asset located in the Shanxi Province , China . The Company was founded in 2005 and has offices in Houston, Texas , Beijing, China , and Lagos, Nigeria .
Investor Relations Contact: ICR 832-209-1419 IR@camacenergy.com
Source: CAMAC Energy Inc.
Awesome :Thumbsup:
I agree :)
At least $7 or near it
But I've seen way too many charts break the "rules" the past couple years...
On support level... been waiting for this
CAMAC Energy, Inc. (CAK) Conference Call Covers Operational and Management Developments
http://missionir.com/blog/small-cap-news/camac-energy-inc-cak-conference-call-covers-operational-and-management-developments/
CAMAC Energy is a Texas-based energy exploration, development, and production company, with oil and gas interests in Nigeria and China. Their Nigerian interests are in OML 120 and 121, offshore oil leases in deepwater Nigeria that started production from the Oyo Field in December of 2009. In China, the company has a 100% interest in the Zijinshan Block gas asset located in Shanxi Province.
The company just completed a conference call for investors, discussing recent events and future strategy, with presentations by the following:
• Dr. Kase Lawal (Chairman & CEO)
• Edward Caminos (Sr. VP & CFO)
• Alan Halsey (Sr. VP of Exploration & Production)
One of the key points covered by the call was the fact that Dr. Lawal would continue as acting CEO for the next 12 months, and has, in support of this, resigned from his executive management roles at other related companies. A search for a new CEO will begin in earnest next year, and will be led by board members Dr. Lee P. Brown, Hazel R. O’Leary, and John Hofmeister. The move was determined to be in the best interest of shareholders, and was intended to provide enough time to identify the best individual to lead CAMAC into the future.
Dr. Lawal went on to talk about the company’s strategy, and their continuing efforts to broaden their portfolio and to develop OML 120 and 121 in Nigeria, working closely with Nigerian Agip Exploration Ltd., a subsidiary of Italian oil company Eni and the technical operator of the field. Ongoing studies should help determine the viability and locations of potential development wells for the field. OML 120 and 121 represent a landmark asset for CAMAC, with soil reports indicating gross oil resources of 627 million barrels, with a high potential estimate of 2.2 billion barrels, and with undiscovered oil estimates as high as 6.3 billion barrels. Of the 8 wells drilled in OML 120 and 121, all have identified hydrocarbons, with no dry wells. The company is working hard with NAE to put in place a more aggressive timeline, with the expectation to communicate a path forward by the end of the 4th quarter.
Edward Caminos summarized financial results for the 2nd quarter, ended in June, with the company reporting a net income of $5.7 million. In June, there was a lifting of roughly 600,000 barrels of crude oil, with a realization of $112.83 per barrel, though the company’s gross share of this was approximately 221,000 barrels. CAMAC’s balance sheet, as of June 30, showed cash and cash equivalents of $11.2 million, with an accounts receivable of $28.2 million. The only debt is a $25 million credit facility provided in June by Allied Energy.
Alan Halsey spoke about the unique opportunity that exists now in West Africa, where major oil companies are looking to divest some of their assets, opening the door for indigenous companies, especially where governments are interested in having a partnership with such companies. He indicated that the oil field has been producing at the rate of approximately 3,650 barrels of oil per day gross from the two wells Oyo 5 & 6, and that they are working to accelerate the timeline for oil field development. In terms of China, the company’s exploration program continues in partnership with PetroChina. The original exploration program was intended to target coalbed methane, but has now expanded to include tar sands and even shale targets.
Unless the current debt deal falls through, I'd put my cards on up
Lol, I can't imagine what that would feel like